长春高新：子公司注射用GenSci143境外临床试验申请获FDA受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance from the US FDA for the clinical trial application of GenSci143, a dual-specific antibody-drug conjugate targeting B7-H3 and PSMA for the treatment of advanced solid tumors [1] Group 1 - GenSci143 is independently developed by Jinsai Pharmaceutical [1] - The clinical trial application for GenSci143 has also been accepted by the National Medical Products Administration in China [1]